Skip to content
WELCOME10 — 10% OFFSHOP NOW →
Research Overview7 min read

ARA-290 (Cibinetide): The EPO Fragment That Left the Blood Behind

Erythropoietin has a tissue-protective activity entirely separate from its effect on red blood cells. ARA-290 is the fragment that isolates it — and unlike most research peptides, it has been through a randomised controlled trial in patients.

ARA-290cibinetideARA-290 canadabuy ARA-290innate repair receptorEPO derived peptidesmall fibre neuropathy researchARA-290 research
By Popular PeptidesPublished Updated

Splitting one hormone into two jobs

Erythropoietin is known for one thing: telling bone marrow to make red blood cells. That is the property that made it a drug, and the property that made it a doping agent.

It also has a second, quite separate activity — a tissue-protective signal that operates through a different receptor complex and has nothing to do with erythropoiesis. For researchers interested in that second job, full-length EPO is a blunt instrument: you cannot study the tissue-protective arm without also driving red cell production.

ARA-290 — cibinetide — is the answer to that problem. It is an 11-amino-acid peptide derived from EPO's tertiary structure, engineered to engage the innate repair receptor while leaving erythropoiesis alone.

Why that separation is the whole point

The innate repair receptor is the tissue-protective arm of EPO signalling. Isolating it means researchers can probe repair and anti-inflammatory pathways without confounding every result with haematocrit changes.

That makes ARA-290 an unusually clean tool. Most research peptides are interesting because of what they do; this one is interesting largely because of what it deliberately does not do.

It has actually been in patients

This is rare enough in a research catalogue to be worth stating plainly.

In a randomised, double-blind pilot study, 22 sarcoidosis patients with symptoms of small fibre neuropathy received either ARA-290 (12 patients) or placebo (10 patients), 2 mg intravenously three times weekly for four weeks. The ARA-290 group showed significant improvement in Small Fiber Neuropathy Screening List score at week 4 versus placebo (p < 0.05), along with gains in pain and physical functioning measures. No safety concerns were identified. Published by Heij, Niesters, Swartjes and colleagues in *Molecular Medicine* in 2012.

Later work reported improvements in corneal nerve fibre abundance in patients with sarcoidosis-associated small nerve fibre loss and neuropathic pain — a structural measure rather than a symptom score, which is a meaningfully harder endpoint to move.

Twenty-two patients is a pilot, not a phase 3, and should be read as one. But a randomised controlled trial with a significant primary result puts ARA-290 well ahead of the typical research compound, which arrives supported by cell-culture work and hope.

Research attention concentrates on neuropathy, nerve repair and inflammation models. Related compounds in the catalogue include BPC-157 in tissue repair models and thymosin alpha-1 in immune modulation. Molecular data for each is in our reference library.

What to check before buying it

An 11-residue peptide with a well-defined structure is straightforward to synthesise correctly and equally straightforward to synthesise badly. Only the certificate tells you which you received.

  • —HPLC for purity, LC-MS for identity, by an independent third-party lab rather than the seller.
  • —Third-party HPLC purity testing, measured by an independent lab.
  • —Certificates of Analysis (COAs) are for members only. Membership is free, and access is released to members in stages.

Then the part that decides whether it arrives at all: shipped from Vancouver, BC, typically 2 to 5 business days, tracked, insured, discreetly packaged, priced in Canadian dollars, free shipping over $300 CAD. No customs clearance and no border seizure, because nothing crosses a border. Most research compounds bought in Canada come from overseas and take that risk on every order.

View ARA-290

Frequently asked questions

What is ARA-290?

ARA-290, also called cibinetide, is an 11-amino-acid synthetic peptide derived from the tertiary structure of erythropoietin. It engages the innate repair receptor — EPO's tissue-protective signalling arm — without stimulating red blood cell production. It is supplied for in vitro laboratory research use only.

Does ARA-290 affect red blood cell production?

No. It was specifically designed to separate EPO's tissue-protective activity from its erythropoietic activity, engaging the innate repair receptor without driving erythropoiesis. That separation is the reason the compound exists.

Has ARA-290 been studied in humans?

Yes. A randomised, double-blind pilot study in 22 sarcoidosis patients with small fibre neuropathy symptoms reported significant improvement in Small Fiber Neuropathy Screening List score at 4 weeks versus placebo (Heij et al., Molecular Medicine, 2012). Later work reported improvements in corneal nerve fibre abundance. These are early-stage findings from small studies.

What research areas use ARA-290?

Primarily neuropathy, nerve repair and inflammation models — research questions concerning tissue protection rather than anything haematological.

Where can I buy ARA-290 in Canada?

Popular Peptides supplies ARA-290 for laboratory research use, shipped domestically from Vancouver, BC. Certificates of Analysis (COAs) are for members only. It is not sold for human or veterinary consumption.

ARA-290 is supplied for in vitro laboratory research use only. It is not approved by Health Canada for therapeutic use and is not intended for human or veterinary consumption. 18+.

Key takeaways

  • ARA-290 (cibinetide) is an 11-amino-acid synthetic peptide derived from the tertiary structure of erythropoietin.
  • It engages the innate repair receptor — the tissue-protective arm of EPO signalling — without stimulating erythropoiesis, which is the entire design objective.
  • A randomised, double-blind pilot study in 22 sarcoidosis patients with small fibre neuropathy symptoms reported significant improvement in SFNSL score at 4 weeks versus placebo (Heij et al., Molecular Medicine, 2012).
  • Subsequent work reported improvements in corneal nerve fibre abundance in patients with sarcoidosis-associated small nerve fibre loss.
  • Research interest centres on neuropathy, nerve repair and inflammation models rather than anything haematological.
  • For in vitro laboratory research use only — not for human or veterinary consumption.

We source from distributors whose batches are third-party tested for HPLC purity and measured content. Certificates of Analysis (COAs) are for members only.